Key facts
- It has raised $1.2B; the latest was Later Stage VC ($1.0B) in Sep 2025.
- Notable investors include Mana Ventures, Team Ignite Ventures, Prosto Venture Club, Selective VC, Immortal Dragons — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Retro Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Retro Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Retro Biosciences
Developer of age-related therapeutics designed to extend healthy human lifespan by targeting the biological mechanisms of aging. The company offers a platform that integrates single-cell multi-omics, pooled perturbation screening, and targeted delivery technologies, enabling biopharmaceutical developers to prevent and reverse age-related diseases through accelerated translation of aging reversal mechanisms into human therapies.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2020
- Employees
- 92
- Website
- retro.bio/
- Ownership
- Privately Held (backing)
Retro Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Retro Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Retro Biosciences in its N-PORT filings yet. We sweep new filings monthly.